Literature DB >> 1668109

L-659,989: a useful probe in the detection of multiple conformational states of PAF receptors.

S B Hwang1, M H Lam.   

Abstract

L-659,989 is a potent, specific and competitive platelet-activating factor (PAF) receptor antagonist. The 2,5-tritium labeled L-659,989, similar to [3H]PAF, specifically binds to rabbit platelet membranes with an equilibrium dissociation constant (KD) of 1.60 (+/- 0.20) nM in 10 mM MgCl2. However, guanosine 5'-triphosphate (GTP) and several cations affect the specific binding of [3H]PAF and of [3H]L-659,989 to rabbit platelet membranes in different ways. K+, Mg2+, Ca2+ and Mn2+ potentiate the specific binding of both ligands. Na+ and Li+ inhibit the specific [3H]PAF binding, but enhance the binding of [3H]L-659,989; GTP reduces the [3H]PAF binding but has no effect on the binding of [3H]-L-659,989. Ni2+ inhibits the [3H]L-659-989 binding, but has no effect on the binding of [3H]PAF. In the presence of 150 mM NaCl, [3H]L-659,989 exhibits identical KD and detectable binding sites (Bmax) values as those in the presence of 10 mM MgCl2, while KD And Bmax values of [3H]PAF are dramatically reduced in the presence of 150 mM NaCl compared to those in 10 mM MgCl2. These results suggest the existence of multiple conformational states of the PAF specific receptor and that PAF and L-659,989 bind differently to those states. In the presence of 150 mM NaCl and 1 mM GTP, receptors appear to exist in a single conformational state with an equilibrium dissociation constant (KB) of 0.93 microM for PAF as derived from the Schild plot. In isolated rabbit platelets pretreated with 10 microM ETH 227, a Na(+)-specific ionophore, the detectable [3H]PAF binding sites drop from 260 to 100 binding sites per platelet, but the binding sites for [3H]L-659,989 remain roughly the same. The Na+ binding sites which modulate the conformation of PAF receptors are therefore protected from extracellular Na+ until ionophore is added, and are probably located on the cytoplasmic side of the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668109     DOI: 10.1007/bf02536520

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  17 in total

1.  Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.

Authors:  S B Hwang; M H Lam; A W Alberts; R L Bugianesi; J C Chabala; M M Ponpipom
Journal:  J Pharmacol Exp Ther       Date:  1988-08       Impact factor: 4.030

2.  Design, properties, and applications of neutral ionophores.

Authors:  W Simon; E Carafoli
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Binding and internalization of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in washed rabbit platelets.

Authors:  H Homma; A Tokumura; D J Hanahan
Journal:  J Biol Chem       Date:  1987-08-05       Impact factor: 5.157

4.  Species difference in the specific receptors of platelet activating factor.

Authors:  S B Hwang; M H Lam
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

5.  Specific binding sites for platelet activating factor in human lung tissues.

Authors:  S B Hwang; M H Lam; T Y Shen
Journal:  Biochem Biophys Res Commun       Date:  1985-04-30       Impact factor: 3.575

6.  Characterization of platelet-activating factor (PAF) receptor by specific binding of [3H]L-659,989, a PAF receptor antagonist, to rabbit platelet membranes: possible multiple conformational states of a single type of PAF receptors.

Authors:  S B Hwang; M H Lam; A H Hsu
Journal:  Mol Pharmacol       Date:  1989-01       Impact factor: 4.436

7.  Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine.

Authors:  F H Valone; E J Goetzl
Journal:  Immunology       Date:  1983-01       Impact factor: 7.397

8.  Presence of specific binding sites for platelet-activating factor (PAF) in brain.

Authors:  M T Domingo; B Spinnewyn; P E Chabrier; P Braquet
Journal:  Biochem Biophys Res Commun       Date:  1988-03-15       Impact factor: 3.575

9.  Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes.

Authors:  S B Hwang; C S Lee; M J Cheah; T Y Shen
Journal:  Biochemistry       Date:  1983-09-27       Impact factor: 3.162

10.  Influence of sodium on the alpha 2-adrenergic receptor system of human platelets. Role for intraplatelet sodium in receptor binding.

Authors:  H J Motulsky; P A Insel
Journal:  J Biol Chem       Date:  1983-03-25       Impact factor: 5.157

View more
  4 in total

1.  Inhibition of leukotriene formation and IL-8 release by the paf-receptor antagonist SM-12502.

Authors:  R A Hilger; M Köller; W König
Journal:  Inflammation       Date:  1996-02       Impact factor: 4.092

2.  Effect of the PAF-receptor antagonist SM-12502 on human platelets.

Authors:  M Köller; R A Hilger; W König
Journal:  Inflammation       Date:  1996-02       Impact factor: 4.092

Review 3.  Platelet-activating factor antagonists.

Authors:  M Koltai; P G Braquet
Journal:  Clin Rev Allergy       Date:  1994

4.  Autocrine enhancement of leukotriene synthesis by endogenous leukotriene B4 and platelet-activating factor in human neutrophils.

Authors:  P P McDonald; S R McColl; P Braquet; P Borgeat
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.